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1. Introduction 
Venous disease continues to increase in number of patients throughout the 2000’s. With 
continued use of venous access devices, dialysis and cancer on the increase and overall 
patient sedentary life style, we will continue to see more and more venous disease in our 
population. Overall, venous disease is far more prevalent in the population than arterial 
disease. However, it is less diagnosed than arterial disease due in part too less acute 
symptomatology. Patients tend to present later in their disease process due to a multitude of 
factors including lack of debilitating symptoms, non-life threatening presentation and 
manageable discomfort until later stages.  
Symptoms like gradual leg swelling in DVT patients, arm swelling in Dialysis fistulas and 
facial edema in superior vena cava (SVC) syndrome are slowly progressive until symptoms 
become debilitating. Even pulmonary emboli can be sub clinical with only non-specific 
findings like dyspnea and chest discomfort. Coumadin and the other low molecular weight 
heparin products are used as outpatient therapies in oral or injection preparations. These are 
adequate therapies for further prevention of clot formation and help resolve clots outside 
the hospital setting. However, weekly blood draws and side effects of these drugs 
particularly in the elderly can be significant and are potential reasons for multiple 
readmissions to the hospitals related to complications from bleeding. 
2. Treatment options 
The standard treatment for deep venous thrombosis and pulmonary is anti-coagulation 
embolism. Intravenous heparin is used in the acute hospital setting. Coumadin and the other 
low molecular weight heparin products are used as outpatient therapies.  
For those patients with significant clot burden within peripheral or pulmonary embolism, 
endovenous therapies can be used if not candidates for anticoagulation. These patients 
present emergently with significant morbidity. In fact, acute extensive DVT of the lower 
extremity can cause severe peripheral vascular arterial emergency called Phlegmasia 
Cereulens Dolans. This disorder needs rapid clot lysis to dissolve the massive clot burden. 
Thus, only catheter directed thrombolysis could provide this direct form of endovenous 
therapy. Whether it is acute, semi acute or chronic venous occlusive process, endovenous 
therapies have become the first line of therapy. If left untreated or inadequately treated with 
conventional means, patients may develop post thrombotic syndrome.  
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Various areas may be treated within the venous distribution. The treatable areas include 
extremity veins, superior venacava, portal vein, inferior venacava, mesenteric veins, renal 
veins, and pulmonary veins. These cases present in various different clinical scenarios based 
on acuity and severity of symptoms. Extremity swelling, pain and positive Doppler duplex 
venous ultrasound are the typical presenting clinical picture. For other venous thromboses, 
more severe clinical sequela are evident in the setting of portal vein and mesenteric vein 
thromboses. If not treated quickly, these can present with severe bowel compromise 
requiring emergent surgery. Computed tomographic angiographic images usually confirm 
the findings. Massive pulmonary emboli can also present as cardiovascular collapse if not 
treated emergently. Various scenarios from life threatening entities to outpatient treatments 
can be approached with endovascular means.  
3. Available devices 
There are many devices now on the market to treat vascular thromboses and in particular 
venous thrombosis. Various types of endovascular devices are now on the market for venous 
thrombolysis. These include the Unifuse and Speed-Lyser infusion catheters (Angiodynamics, 
Queensbury, New York), Possis AngioJet Ultra thrombectomy system (Medrad, Minneapolis, 
Minnesota), EKOS endowave endovascular system (EKOS Corporation, Bothell, WA), Trellis 
peripheral infusion system (Bacchus Vascular, Santa Clara, CA), Spectranetics Turbo Elite 
Laser Ablation catheter (Spectranetics, Colorado Springs, CO) and a pure aspiration catheter 
called the Pronto Extraction catheter (Vascular Solutions, Minneapolis, MN). 
There are three different types of catheter systems. One catheter is just used for thrombolytic 
drug infusion (Speed-Lyser and Uni-Fuse). The second sets of catheter systems are combined 
devices using both mechanical and pharmacological thrombolysis (EKOS endowave, Possis 
angiojet, and Trellis thrombectomy) The third set of devices use only mechanical 
thrombectomy (Possis angiojet, Spectranectics laser ablation and Pronto extraction catheter). 
4. Thrombolysis/Infusion catheters 
These catheters systems are the original type for thrombolysis. The Uni fuse is a single 
catheter system with multiple side holes throughout its infusion length. (Fig 1) They infuse 
drug directly into the clot and allow the drug to act directly on the thrombus intraluminally. 
The catheters come in various sizes and lengths. The speed lyser catheter is unique short 
device with only 15 and 20cm lengths. This device is designed to be used during fistulalysis 
procedures for dialysis patients. Both catheter systems are excellent for clot dissolution due 
to their ease of use and ability to use any drug combination.  
5. Combination mechanical and pharmacological thrombolysis catheters 
These devices combine both mechanical dissolution and pharmacological thrombolysis to 
the clot. The devices include EKOS endowave system, Trellis peripheral infusion system and 
the Possis Angiojet system. The EKOS system is the newest of the devices. EKOS uses 
ultrasonic agitation of the clot with drug infusion to speed the clot lysis. This helps clear the 
large bulky clot typically seen in the venous system. (Fig 2) (Fig 3) The large clot burden in 
the legs and pulmonary arteries are ideal for this device. Theoretically, there is less drug 
used and less infusion time resulting in less intensive care monitoring and lessening the cost 
of the hospital stay. (Fig 4)  
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A) 
 
B) 
 
C) 
Fig. 1. 64 y/o female with left leg swelling and pain and a positive U/S for DVT A) 
Extensive DVT Left SFV extending into iliac system B) EKOS Endowave combination 
thrombolysis catheter in place with TNK infusion overnight C) Widely patent ilio-femoral 
venous system following thrombolysis 
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A)           B) 
 
     
C)           D) 
 
    
E) 
Fig. 2. 39 y/o female with May-Thurner Syndrome presents with left leg swelling, pain and 
+ DVT A) Extensive DVT left leg B) Pure thrombolytic therapy performed with Unifuse 
catheter system and TNK for overnight infusion C) Uncovered irregular stenosis Left iliac 
vein D) Balloon venoplasty performed with improved appearance but residual stenosis 
remains E) Iliac venous stent placed now with widely patent venous flow through iliac veins 
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A) 
 
 
B) 
 
 
C) 
Fig. 3. 54 y/o male with bilateral leg DVT and ilio-caval DVT  
A) Extensive ilio-caval thrombus B) and C) Kissing EKOS catheters placed simultaneously 
with TNK initiated for overnight infusion now with widely patent iliac veins and venacava 
on final images 
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A)     B) 
  
C)     D) 
Fig. 4. 71 y/o male with cardiopulmonary collapse/shock with bilateral pulmonary 
embolism A) and B) Bilateral extensive pulmonary embolism C) Bilateral simultaneous 
EKOS/TNK combination thrombolysis catheters in place D) Widely patent pulmonary 
arteries following 12 hour infusion  
The Trellis device also combines mechanical and pharmacological thrombolysis. This device 
comes in various lengths and uses balloon occlusion technique to focus on the segmental 
clot burden. The “whip like” mechanical disruption breaks up the clot allowing the drug to 
act more effectively. (Fig 5) This is a useful device for isolated clot and can be performed as 
an outpatient with need for hospital admission.  
The Possis AngioJet system can be both a pure mechanical and combination mechanical and 
pharmacological thrombolytic system. For combined systems, the Possis catheter is used in a 
“power pulse spray mode” where the thrombolytic drug is pulse sprayed directly into the 
clot. It is then allowed to sit in the vessel and dissolve the clot and then is removed by the 
standard angiojet thrombectomy fashion. This device can be used in many venous 
distributions with its various lengths and catheter treatment diameters. (Fig 6) 
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A) 
 
 
B) 
 
 
C) 
Fig. 5. 59 y/o male with extensive DVT left leg swelling and pain  
A) Extensive DVT identified B) Trellis thrombectomy device in SFV with balloon occlusion 
and mixed mechanical and pharmacological thrombolysis C) Marked improvement 
following Trellis device  
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A)     B) 
  
C) 
Fig. 6. 61 y/o male with chronic pancreatitis with portal vein thrombosis A) Extensive portal 
vein thrombosis as seen on this transhepatic portogram B) Power pulse spray possis angiojet 
and TPA thrombolysis of the portal vein C) Improved patency of portal vein  
6. Pure mechanical devices 
These devices require no thrombolytic agent to be infused into the vessel. The devices are 
the Possis angiojet catheter, Spectranectics laser catheter and Pronto extraction catheter. The 
Possis system uses saline jet through its distal side holes to create a Bernoulli effect thereby 
removing clot without need for drug therapy. (Fig 7) The Spectranectic device uses laser 
technology to vaporize the clot and thereby clear the vessel of clot quickly without chance of 
distal embolic phenomenon. They also come in various sizes for different vessel territories. 
This device can also be used as an outpatient without need for overnight stay.  
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The Pronto catheter (Pronto .035 extraction catheter, Vascular Solutions, Inc., Minneapolis, 
MN) is the newest pure mechanical device. Previously, developed from coronary 
interventions, it is now made for venous interventions. Pure aspiration catheters with large 
8 French end hole-guiding catheters are used for cases with large clot burden such as 
massive pulmonary embolism and extensive deep venous thrombosis.  
 
   
A     B 
  
C)     D) 
Fig. 7. 31 y/o body building male with dominant right arm swelling and pain c/w Paget 
Schroetter syndrome A) Possis angiojet pure thrombectomy device cleared clot from 
subclavian vein B) Uncovered focal irregular stenosis in subclavian vein which is worse 
with adduction arm motion C) Balloon Venoplasty of right subclavian vein D) Patent right 
subclavian vein with all degrees of motion the right arm on final images  
7. Additional venous interventions  
Following mechanical or pharmacological thrombolysis for acute venous thrombolysis, 
additional endovascular interventions are usually necessary. Whether, there are focal 
stenoses uncovered following intervention as in Paget Schroetter syndrome, May -Thurner 
syndrome or fistula anastomoses in dialysis graft, there is typically some element of recoil in 
the vein, fixed stenosis or some chronic residual thrombus. Further interventions are 
required involving balloon venoplasty, stent placement or filter placement.  
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8. Balloon venoplasty  
Balloon venoplasty can be performed after the bulky thrombus has been removed 
uncovering an underlying venous stenosis. This can be treated with venoplasty to improve 
the diameter of the vessel thus improving its flow. It is the gold standard for venous stenosis 
in various distributions including subclavian, iliac or venacava corresponding to the various 
syndromes described previously. Typically, these interventions treat the underlying venous 
stenosis resulting in venous patency. The more central the venous stenosis, the better the 
result following venoplasty. Recurrent or residual venous stenosis following balloon 
venoplasty occurs frequently especially in those patients with chronic central venous 
catheters. Despite venoplasty, these venous lesions are very difficult to treat and recurrent 
venous stenosis may require stenting  
9. Venous stenting  
Stents can be used in any venous distribution from peripheral to central veins. Covered and 
uncovered metal stents can be used for recurrent stenosis. Central venous stenosis as in the 
SVC and IVC require the largest available stents. Covered stents and the newest Flair 
covered stent (CR Bard, Tempe, AZ) are now available for dialysis fistula anastomoses 
where by a smaller fistula graft enters into the larger native venous outflow resulting in a 
smooth transition and improve flow dynamics. Venous stenting can also be performed 
following suboptimal balloon venoplasty result. Venous stenting is not performed on 
thrombus alone but is used as an adjunct to suboptimal venoplasty and venous 
thrombolysis.   
10. Thrombolytic agents 
Activase (TPA) (Genenetech, South San Francisco, CA) and Tenecteplase (TNK) 
(Genenetech, South San Francisco, CA) are the most common thrombolytic agents currently 
available. These drugs are fibrinolytic agents which break down fibrin into split products 
thus allowing clot to lyse within the vascular system. In the veins, both work similarly but 
TNK seems to lyse clot faster with less bleeding complications due to its exquisite fibrin 
specificity. Tenecteplase is the newer of the two agents. It has a 14 fold higher fibrin binding 
specificity than TPA. Due to the larger volume of clot within veins, a larger dose of drug is 
necessary to lyse the clot burden. This is one of the reasons for combining mechanical with 
thrombolytic agents. With combination therapy, less drug can be used in these larger 
capacitance vessels if combined with one of the above-mentioned mechanical devices. 
11. Dialysis Interventions 
Dialysis fistulas grafts are increasing in number, as renal failure becomes an epidemic. 
Failure of these grafts is frequent and accounts for most of the morbidity associated with 
these grafts.  Immediate graft malfunction due to surgical causes is quickly identified during 
placement. Acute thrombosis within these grafts can occur at any time following placement. 
This is a constant problem for nephrologists due to the nature of hemodialysis itself. 
Chronic needle punctures within the graft 3-4 times a week results in numerous chances for 
thrombus formation. Also, heparinization during hemodialysis and then reversing the 
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coagulation during and after dialysis catheter removal results in thrombosis of the graft. If 
unable to open the graft within a reasonable time, then other means of vascular access are 
required. Typically, another central venous dialysis catheter is needed until a new graft is 
created or the present one is cleaned out.  
Interventional doctors are well adapted to lysis of dialysis graft using both pure 
pharmacological and mechanical thrombectomy. These grafts can be cleared of their 
thrombus burden in the interventional lab without requiring further surgery. Pure 
thrombolysis catheters like Speed Lyser delivers drug directly to the clot through multi-side 
holes via one micro catheter system. The drug is allowed to sit within the graft and dwell for 
a period of time called “lyse and wait” technique.  Over this period of time, the clot is lysed 
and the graft is cleared of thrombus. TPA is used for this purpose. It can be injected directly 
into a graft. TPA can be given as a 6mg bolus within the dialysis grafts for this treatment. 
Following lysis, other interventions may be necessary to alleviate the source of the 
underlying graft malfunction.  
12. Inferior venacava filter placement 
Caval thrombosis can be acute or chronic. Filters can be used for the treatment of acute caval 
thrombosis, prophylaxis of pulmonary embolism and also be the source of caval thrombosis. 
Both treatment and cause of caval thrombosis makes interruption filters a double-edged 
sword. Either way, endovenous means are used exclusively for caval thrombosis.  
Furthermore, most of the patients undergoing venous thrombolysis receive retrieval Inferior 
Vena Cava filter before the intervention. This is usually placed at the same setting. This idea 
is to reduce the risk of an iatrogenic fatal pulmonary embolism during the procedure. This 
filter can then be removed if indicated up to six months following implantation. Prior to 
removing the filter, a duplex venous ultrasound of the lower extremities is obtained to 
document clot resolution.  
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